Cited by 115Cancer-related Molecular PathwaysSarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Ito, Moriko, Barys, Louise, O'Reilly, Terence, Young, Sophie, Gorbatcheva, Bella, Monahan, John, Zumstein-Mecker, Sabine, Choong, Peter F., Dickinson, Ian, Crowe, Philip, Hemmings, Christine, Desai, Jayesh, Thomas, David M., Lisztwan, Joanna·2011·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-2050

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Reactivation of p53 tumor suppressor activity in diseases such as soft-tissue sarcoma is considered an attractive means of targeted therapy. By systematically assessing alterations affecting the p53 pathway, we aimed to (a) classify sarcoma subtypes, (b) define a potential role in malignancy, and (c) identify potential patient biomarkers in this heterogeneous disease. Experimental Design: We have mapped mutational events in a panel of 192 benign or malignant bone and soft-tissue sarcomas. Analyses included TP53 and CDKN2A mutational and SNP status, MDM2 and MDM4 amplification and MDM2 SNP309 status. Results: We found an inverse relationship between MDM2 amplification and TP53 mutations, with a predominantly wild-type CDKN2A background. A high rate of point mutations in TP53 was observed uniquely in leiomyosarcoma, osteosarcoma, and MFH. Both MDM2 and MDM4 were also amplified in a subtype-specific manner, which was frequently seen as a coamplification event. We have also analyzed the risk allele frequencies for MDM2 SNP309, and show that the G allele was strongly associated with both liposarcomas and MDM2 amplification. Conclusions: Our data emphasize the critical role of p53 inactivation in sarcomagenesis, whereby different pathway alterations may be related to the heterogeneity of the disease. Moreover, we observed a strong association of malignancy with TP53 mutation, or MDM2 amplification and the presence of a G allele in SNP309, especially in lipoma versus liposarcoma. We propose, therefore, that MDM2 markers along with TP53 sequencing should be considered as patient biomarkers in clinical trials of sarcomas using MDM2 antagonists. Clin Cancer Res; 17(3); 416–26. ©2010 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2050

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Biostatistical Analysis
Baltosser, W. H., & Zar, J. H. (1996) · Ecology · doi:10.2307/2265725 · Cited by 35,166
Biostatistical analysis
Zar, J. H. (1996) · Cited by 7,837
Biostatistical Analysis (2nd ed.).
Breen, T. J., & Zar, J. H. (1986) · Journal of the American Statistical Association · doi:10.2307/2289268 · Cited by 5,792
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“A central regulator of p53 is the proto-oncogene Mdm2, which functions as an E3 ubiquitin ligase promoting p53 degradation (3, 4).”
Background
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 4×
“Somatic p53 mutations have been reported in 20% to 33% of all sarcomas (2, 18).”
BackgroundInfluential
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286

Show all 57 references

Research works printed but not linked: 1

Brown, 2009, Awakening guardian angels: drugging the p53 pathway, Nat Rev Cancer, 9, 862, 10.1038/nrc2763 · DOI · Paper page

Sorted by citations

MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3087 · Cited by 444
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 345
Self-citation
Integrative genomic and transcriptomic analysis of leiomyosarcoma
Chudasama, P., Mughal, S. S., Sanders, M. A., Hübschmann, D., Chung, I., Deeg, K. I., Wong, S.-H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02602-0 · Cited by 316
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors
Lechner, M., Frampton, G. M., Fenton, T. R., Feber, A., Palmer, G. A., Jay, A., Pillay, N., Forster, M. D., Cronin, M. T., Lipson, D., et al. (2013) · Genome Medicine · doi:10.1186/gm453 · Cited by 219
Epidemiology and Etiology of Sarcomas
Hui, J. Y. C. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.05.005 · Cited by 217
Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy
Nielsen, T. O., Poulin, N., & Ladanyi, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1246 · Cited by 172
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 156
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 140
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas
Italiano, A., Chen, C., Thomas, R. J., Breen, M., Bonnet, F., Sévenet, N., Longy, M., Maki, R. G., Coindre, J., & Antonescu, C. R. (2012) · Cancer · doi:10.1002/cncr.27614 · Cited by 126
Targeted genomic analysis of Müllerian adenosarcoma
Howitt, B. E., Sholl, L. M., Cin, P. D., Jia, Y., Yuan, L., MacConaill, L. E., Lindeman, N. I., Kuo, F. C., Garcia, E. P., Nucci, M. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4442 · Cited by 115
A “Twist box” Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation
Piccinin, S., Tonin, E., Sessa, S., Demontis, S., Rossi, S., Pecciarini, L., Zanatta, L., Pivetta, F., Grizzo, A., Sonego, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.003 · Cited by 121
Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma
Zhang, Q. H., Ubago, J. M., Li, L., Guo, H., Liu, Y., Qiang, W., Kim, J. J., Kong, B., & Wei, J. (2014) · Cancer · doi:10.1002/cncr.28900 · Cited by 93
The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity
Michaloglou, C., Lehmann, W., Martin, T., Delaunay, C., Hueber, A., Barys, L., Niu, H., Billy, É., Wartmann, M., Ito, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061916 · Cited by 94
Self-citation
Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.
Yang, C., Liau, J., Huang, W., Chang, Y., Chang, M., Lee, J., Tsai, J., Su, Y., Hung, C., & Jeng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 88
Analysis ofMDM2Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
Kato, S., Ross, J. S., Gay, L. M., Dayyani, F., Roszik, J., Subbiah, V., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00235 · Cited by 77
High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes
Choy, E., Hornicek, F. J., MacConaill, L. E., Harmon, D. C., Tariq, Z., Garraway, L. A., & Duan, Z. (2011) · Cancer · doi:10.1002/cncr.26617 · Cited by 70
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., Alexe, G., Schauer, N. J., Liu, X., Bird, G. H., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171066 · Cited by 69
Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F. A. S., Repapi, E., Grochola, L. F., Bartel, F., Hogendoorn, P. C. W., Wuerl, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0215 · Cited by 65
The pharmacogenomics of osteosarcoma
Serra, M., & Hattinger, C. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.45 · Cited by 65
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment
Urso, L., Calabrese, F., Favaretto, A. G., Conte, P., & Pasello, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.019 · Cited by 54
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 53
Targeted exome sequencing profiles genetic alterations in leiomyosarcoma
Agaram, N. P., Zhang, L., Loarer, F. L., Silk, T., Sung, Y., Scott, S. N., Kuk, D., Qin, L., Berger, M. F., Antonescu, C. R., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22318 · Cited by 50
The MDM2 RING Domain and Central Acidic Domain Play Distinct Roles in MDM2 Protein Homodimerization and MDM2-MDMX Protein Heterodimerization
Leslie, P. L., Ke, H., & Zhang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.644435 · Cited by 50
Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis
Guled, M., Pazzaglia, L., Borze, I., Mosakhani, N., Novello, C., Benassi, M. S., & Knuutila, S. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22179 · Cited by 44
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O. (2012) · Cancer · doi:10.1002/cncr.27837 · Cited by 42
Targeting Mdmx to treat breast cancers with wild-type p53
Haupt, S., Buckley, D., Pang, J.-M., Panimaya, J., Paul, P. J., Gamell, C., Takano, E. A., Lee, Y. Y., Hiddingh, S., Rogers, T.-M., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.173 · Cited by 42
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 43
Genomic gain of RRS1 promotes hepatocellular carcinoma through reducing the RPL11-MDM2-p53 signaling
Cao, P., Yang, A., Li, P., Xia, X., Han, Y., Zhou, G., Yang, F., Yang, F., Li, Y., Cui, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4304 · Cited by 42
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
The selected biomarker analysis in 5 types of uterine smooth muscle tumors
Zhang, Q., Kanis, M. J., Ubago, J. M., Liu, D., Scholtens, D. M., Strohl, A. E., Lurain, J. R., Shahabi, S., Kong, B., & Wei, J. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.12.005 · Cited by 38
Advances in sarcoma gene mutations and therapeutic targets
Gao, P., Seebacher, N. A., Hornicek, F. J., Guo, Z., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.001 · Cited by 37
Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas
Lee, D. H., Forscher, C. A., Vizio, D. D., & Koeffler, H. P. (2015) · Scientific Reports · doi:10.1038/srep12580 · Cited by 33
Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma
Yang, J., Annala, M., Ji, P., Wang, G., Zheng, H., Codgell, D., Du, X., Fang, Z., Sun, B., Nykter, M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0076-2 · Cited by 33
FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations
Gambella, A., Bertero, L., Rondón‐Lagos, M., di Cantogno, L. V., Rangel, N., Pitino, C., Ricci, A. A., Mangherini, L., Castellano, I., & Cassoni, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021342 · Cited by 32
The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma
Sioletic, S., & Scambia, G. (2019) · Cancers · doi:10.3390/cancers11081169 · Cited by 32
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 33
Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling
Guijarro, M. V., Dahiya, S. M., Danielson, L. S., Segura, M. F., Vales-Lara, F. M., Menéndez, S., Popiolek, D. A., Mittal, K., Wei, J., Zavadil, J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.035 · Cited by 29
Mouse models of sarcomas: critical tools in our understanding of the pathobiology
Post, S. M. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-20 · Cited by 26
Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma
Harwood, J. L., Alexander, J. H., Mayerson, J. L., & Scharschmidt, T. J. (2015) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.06.011 · Cited by 25
Classification, Molecular Characterization, and the Significance ofPtenAlteration in Leiomyosarcoma
Grossmann, A. H., Layfield, L. J., & Randall, R. L. (2012) · Sarcoma · doi:10.1155/2012/380896 · Cited by 23
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
Hattinger, C. M., Patrizio, M. P., Luppi, S., & Serra, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134659 · Cited by 23
XI-006 induces potent p53-independent apoptosis in Ewing sarcoma
Pishas, K. I., Adwal, A., Neuhaus, S. J., Clayer, M., Farshid, G., Staudacher, A. H., & Callen, D. F. (2015) · Scientific Reports · doi:10.1038/srep11465 · Cited by 23
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
Cheng, J., Yan, Z., Jiang, K., Liu, C., Xu, D., Lyu, X., Hu, X., Zhang, S., Zhou, Y., Li, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01815 · Cited by 22
Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells
Lee, M.-Y., Marina, M. E., King, J. L., & Saavedra, H. I. (2014) · Cell Division · doi:10.1186/1747-1028-9-3 · Cited by 24
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8999 · Cited by 21
The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis
Cai, X., & Yang, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1124-8 · Cited by 21
Inhibition of NADPH oxidase 2 induces apoptosis in osteosarcoma: The role of reactive oxygen species in cell proliferation
Kitamoto, K., Miura, Y., Karnan, S., Ota, A., Konishi, H., Hosokawa, Y., & Sato, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.8291 · Cited by 21
Optimal Clinical Management and the Molecular Biology of Angiosarcomas
Chen, T. W., Burns, J., Jones, R. L., & Huang, P. H. (2020) · Cancers · doi:10.3390/cancers12113321 · Cited by 22
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 21
In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas
Bozzi, F., Conca, E., Laurini, E., Posocco, P., Sardo, A. L., Jocollé, G., Sanfilippo, R. G., Gronchi, A., Perrone, F., Tamborini, E., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.107 · Cited by 20
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas
Chinyengetere, F., Sekula, D., Lu, Y., Giustini, A. J., Sanglikar, A., Kawakami, M., Ma, T., Burkett, S. S., Eisenberg, B. L., Wells, W. A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1883-8 · Cited by 20
Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex
Gerarduzzi, C., de Polo, A., Liu, X.-S., El Kharbili, M., Little, J. B., & Yuan, Z.-M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752303 · Cited by 19
Estimating TP53 Mutation Carrier Probability in Families with Li–Fraumeni Syndrome Using LFSPRO
Peng, G., Bojadzieva, J., Ballinger, M. L., Li, J., Blackford, A. L., Mai, P. L., Savage, S. A., Thomas, D. M., Strong, L. C., & Wang, W. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0695 · Cited by 19
Self-citation
Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis
Wang, L., Liu, Z., Jing, P., Shao, L., Chen, L., He, X., & Gong, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-1227-8 · Cited by 18
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
Buchakjian, M. R., Merritt, N. M., Moose, D. L., Dupuy, A. J., Tanas, M. R., & Henry, M. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183469 · Cited by 18
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas
Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
Landuzzi, L., Manara, M. C., Pazzaglia, L., Lollini, P., & Scotlandi, K. (2023) · Cancers · doi:10.3390/cancers15153887 · Cited by 19
The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts
Bandopadhayay, P., Jabbour, A. M., Riffkin, C. D., Salmanidis, M., Gordon, L., Popovski, D., Rigby, L., Ashley, D. M., Watkins, D. N., Thomas, D. M., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-585 · Cited by 18
Self-citation
Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis
Benna, C., Simioni, A., Pasquali, S., Boni, D. D., Rajendran, S., Spiro, G., Colombo, C., Virgone, C., DuBois, S. G., Gronchi, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24719 · Cited by 16
A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility
for the Slovenian Osteosarcoma Study Group, Bilbao‐Aldaiturriaga, N., Ostolaza, Z. A., Granado-Tajada, I., Goričar, K., Dolžan, V., García‐Miguel, P., de Andoín, N. G., Martín‐Guerrero, I., & García‐Orad, Á. (2016) · Pediatric Research · doi:10.1038/pr.2016.120 · Cited by 15
Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study
Mirili, C., Paydaş, S., Güney, İ. B., Oğul, A., Gökçay, S., Büyükşimşek, M., Yetişir, A. E., Karaalioğlu, B., Tohumcuoğlu, M., & Şeydaoğlu, G. (2019) · Cancer Management and Research · doi:10.2147/cmar.s191199 · Cited by 15
Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15
Targeted therapy in sarcomas other than GIST tumors
Sborov, D. W., & Chen, J. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23802 · Cited by 15
Molecular analyses in the diagnosis and prediction of prognosis in non-GIST soft tissue sarcomas: A systematic review and meta-analysis
Kandel, R. A., Yao, X., Dickson, B. C., Ghert, M. A., Popović, S., Purgina, B., Verma, S., & Werier, J. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.005 · Cited by 14
The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma
Han, J., Hu, Y., Ding, S., Liu, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974916 · Cited by 12
Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis
Huang, X., Wu, F., Zhang, Z., & Shao, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20181832 · Cited by 12
Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors
Chen, L., Li, J., Wu, X., & Zheng, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687899 · Cited by 11
The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 11
Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma
Yang, J. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10209 · Cited by 10
MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction
Mauro, I. D., Mescam-Mancini, L., Chetaille, B., Lae, M. E., Pierron, G., Dadone‐Montaudié, B., Bazin, A., Bouvier, C., Michiels, J., & Pédeutour, F. (2020) · Neoplasia · doi:10.1016/j.neo.2020.05.003 · Cited by 10
Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas
Qin, J., Chen, B., Li, C., Yan, J., & Lu, H. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.11.004 · Cited by 10
Mammalian models of bone sarcomas
Botter, S. M., Arlt, M., Born, W., & Fuchs, B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00030-3 · Cited by 10
Novel Approaches to Treatment of Leiomyosarcomas
Collins, I. M., & Thomas, D. M. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0173-0 · Cited by 8
Self-citation
Sinusoidal-type Angiosarcoma of the Liver: Imaging Features and Potential Diagnostic Utility of p53 Immunostaining
Zen, Y., & Sofue, K. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001349 · Cited by 8
The Combined Immunohistochemical Expression of GLI1 and BCOR in Synovial Sarcomas for the Identification of Three Risk Groups and Their Prognostic Outcomes: A Study of 52 Patients
Giner, F., Medina-Ceballos, E., López-Reig, R., Machado, I., López‐Guerrero, J. A., Navarro, S., Rubio-Martínez, L. A., Espino, M., Mayordomo‐Aranda, E., & Llombart-Bosch, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147615 · Cited by 7
Recurrent Osteosarcoma Presenting as an Isolated Bone Marrow Relapse
Liu, J. C., Cranmer, L. D., Larsen, B. T., Kuo, P. H., & Kopp, L. M. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000719 · Cited by 7
Biological characterization of soft tissue sarcomas.
Hayashi, T., Horiuchi, A., Sano, K., Kanai, Y., Yaegashi, N., Aburatani, H., & Konishi, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.12.33 · Cited by 7
Premalignant Conditions of Bone
Eckhoff, M. D., Wells, M. E., Padilla, O., Polfer, E. M., Castagno, C. J., Thabet, A. M., Elzamly, S., Wilson, H. L., & Rajani, R. (2022) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-22-00097 · Cited by 7
TP53-Deficient Angiosarcoma Expression Profiling in Rat Model
Smyczyńska, U., Strzemecki, D., Czarnecka, A. M., Fendler, W. M., Fiedorowicz, M., Wełniak-Kamińska, M., Guzowska, M., Synoradzki, K. J., Cheda, Ł., Rogulski, Z., et al. (2020) · Cancers · doi:10.3390/cancers12061525 · Cited by 5
Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review
Remiszewski, P., Siedlecki, E., Wełniak-Kamińska, M., Mikuła, M., & Czarnecka, A. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01717-8 · Cited by 4
A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
Chen, X., Cao, L., Xie, N., Xu, X., Liu, M., & Wang, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.46 · Cited by 3
A rare case of dedifferentiated liposarcoma of the sinonasal cavity: A case report
Miyazaki, M., Aoki, M., Oba, S., Sakata, T., Nakagawa, T., & Nabeshima, K. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1379 · Cited by 3
Long telomeres cooperate with p53, MDM 2, and p21 polymorphisms to raise pediatric solid tumor risk
Borbora, D., Dutta, H. K., Devi, K. R., Mahanta, J., Medhi, P., & Narain, K. (2019) · Pediatrics International · doi:10.1111/ped.13915 · Cited by 3
Identification of the 12q15 Amplicon within the Homogeneously Staining Regions in the Embryonal Rhabdomyosarcoma Cell Line RMS-YM
Kakazu, N., Yamane, H., Miyachi, M., Shiwaku, K., & Hosoi, H. (2014) · Cytogenetic and Genome Research · doi:10.1159/000357930 · Cited by 3
Multidisciplinary sarcoma care
Pollock, R. E., Payne, J. E., Rogers, A. D., Smith, S. J., Iwenofu, O. H., Valerio, I. L., Zomerlei, T. A., Howard, J. H., Dornbos, D., Galgano, M. A., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.10.006 · Cited by 3
Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systematic review and meta-analysis”
Bilbao‐Aldaiturriaga, N., Martín‐Guerrero, I., & García‐Orad, Á. (2014) · Tumor Biology · doi:10.1007/s13277-014-1882-4 · Cited by 2
The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies
Deng, W., Gao, S., Yan, L., Su, Q., & Chen, S. (2026) · Pharmaceuticals · doi:10.3390/ph19030476 · Cited by 1
Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis
Tang, J., Shen, L., Song, S., An, Z., & Zhang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1106-3 · Cited by 1
Meta-analisien erabilgarritasunaren analisi kritikoa
Bilbao‐Aldaiturriaga, N., Martín‐Guerrero, I., Gutiérrez-Camino, Á., López-López, E., & García‐Orad, Á. (2014) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.11767 · Cited by 1
The MDM2 SNP309 G allele is not preferentially amplified in bone and soft tissue tumors
Mertens, F., Brosjö, O., von Steyern, F. V., Nord, K. H., & Mandahl, N. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.06.001 · Cited by 1
Molecular Pathology and Novel Therapy for Uterine Sarcomas
Hayashi, T., Sano, K., Ichimura, T., Kawano, M., Kanai, Y., Shiozawa, T., Yaegashi, N., & Konishi, I. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-2489-4_9 · Cited by 1
Nouvelles perspectives et biomarqueurs dans le diagnostic et la prise en charge des tumeurs gynécologiques
Devouassoux‐Shisheboran, M., & Croce, S. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2204-3 · Cited by 1
Expression levels of MDM2 and MDMX proteins and their associated effects on P53 in human liposarcomas
Touqan, N. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Quantitative Assessment of the Association Between HDMX Polymorphism and Sarcoma
Xu, H., Zhou, P., Ti, Y., & Jia, F. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0111-5
Molecular Approaches for Understanding of the Uterine Malignant Mesenchymal Tumours
Hayashi, T. (2015) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.20150305.14
LOODUS- JA TEHNOLOOGIATEADUSKOND MOLEKULAAR- JA RAKUBIOLOOGIA INSTITUUT
Ülikool, T. (2015)
Gene and proteomic profiling of osteosarcoma
Patiño‐García, A., & Lecanda, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00020-0
Candidate Molecules as Tumor Suppressor for Human Uterine Mesenchymal Tumor
Hayashi, T. (2013) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-0381031-37

Authors: Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., Hemmings, C., Desai, J., Thomas, D. M., & Lisztwan, J.
Affiliations: Peter MacCallum Cancer Centre (AU)
Authors' Affiliations: 1Novartis Institutes for Biomedical Research, Oncology Research, Basel, Switzerland; 2Peter MacCallum Cancer Centre, Melbourne, Australia; 3Novartis Institutes for Biomedical Research, Oncology Translational Medicine, Cambridge, Massachusetts; 4Wesley Research Institute, Brisbane, Australia; 5Prince of Wales Hospital, Sydney, Australia; and 6Canberra Hospital, Canberra, Australia
ORCID: Monahan, John
Choong, Peter F.
Crowe, Philip
Hemmings, Christine
Desai, Jayesh
Thomas, David M.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-02-01
Volume: 17
Issue: 3
Pages: 416-426
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-2050
OpenAlex: W2056955003
Cited by: 115
References: 57
Citations by year: 2026: 3 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 7 · 2016: 9 · 2015: 17 · 2014: 16 · 2013: 10 · 2012: 10
FWCI: 3.80
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
ANU Open Research (Australian National University) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: p53 pathway, sarcomagenesis, soft tissue sarcoma, MDM2 amplification, TP53 mutation, CDKN2A, MDM2 SNP309, liposarcoma, lipoma, leiomyosarcoma, osteosarcoma, sarcoma subtypes, MDM2 inhibitors, tumor suppressor inactivation
MeSH terms: Bone Neoplasms, Chromosome Mapping, Gene Amplification, Humans, Mutation, Sarcoma, Soft Tissue Neoplasms, Biomarkers, Tumor, Genes, p53, Gene Dosage, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks